StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) stock

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)

Close on Nov 17, 2026Market cap $3.73BP/E –Yield –

Earnings

Tango Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 4, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$0
-100.0% on a year earlier
EPS, Q3 FY2026
-$0.39
$0.13 a year earlier
Latest guidance
Issued
Aug 5, 2025 · 1 item

Quarterly results

Revenue and earnings per share from each of Tango Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 4, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 9, 2026before the open$0-100.0%-$0.39Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026before the open$0-100.0%-$0.37Release
Q1 FY2026ended Mar 31, 2026May 13, 2026after the close$0-100.0%-$0.32Release
Q4 FY2025ended Dec 31, 2025Mar 5, 2026before the open$0-100.0%-$0.29Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025before the open$53.80M+363.5%$0.13Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025before the open$3.18M-84.0%-$0.35Release
Q1 FY2025ended Mar 31, 2025May 12, 2025before the open$5.40M-16.9%-$0.36Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open$4.10M-24.1%-$0.35Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024before the open$11.61M+8.5%-$0.27Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024before the open$19.88M+36.1%-$0.24Release
Q1 FY2024ended Mar 31, 2024May 8, 2024before the open$6.50M+12.1%-$0.35Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Tango Therapeutics guided for has been reported

Guidance vs results

The last range Tango Therapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2025Revenue$53.80M$53.80MWithin range

Guidance history

Every forecast Tango Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 5, 2025revenueQ3 FY2025$53.80MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Tango Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Results
  5. Update
  6. Update
  7. Update
  8. Results
  9. Update
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?